Skip to main content
. 2020 Dec 4;128(4):621–624. doi: 10.1111/bcpt.13537

Figure 1.

Figure 1

Inhibitory activity of nilotinib in Vero‐E6 and Calu‐3 cells. Cells were infected with SARS‐CoV‐2 and 1 h post‐inoculation treated with serial dilutions of nilotinib. The infection rate was evaluated at 48 hpi for Vero‐E6 and at 24 hpi for Calu‐3 cells. Results are mean and SEM of 3 independent experiments performed in duplicate